Drivers for Changes in the Evidence Generating Network for Biopharmaceuticals: The Impact of the COVID Pandemic

Chyn Wee () and Matthias Mahn ()
Additional contact information
Chyn Wee: lnceptua GmbH
Matthias Mahn: Pfizer Pharma GmbH

A chapter in Life Science Management, 2022, pp 145-167 from Springer

Abstract: Abstract Today, big pharma collaborates with numerous service providers for any R&D activity from lead identification, assay designing, to planning, running, evaluating, or publishing clinical trials. As a result, an Evidence Generating Network has emerged that features specific characteristics like strong network ties and intensity, high mutual reciprocity, clarity of expectations, independency, and centrality. Naturally, progress in science and technology, demographic, political, economic developments as well as increased demand and availability of data, are constantly shaping this dynamic network making it more complex and versatile. This paper reviews impact of the COVID-19 pandemic on further development of the Evidence Generation Network and its main stakeholders.

Date: 2022
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:mgmchp:978-3-030-98764-0_10

Ordering information: This item can be ordered from
http://www.springer.com/9783030987640

DOI: 10.1007/978-3-030-98764-0_10

Access Statistics for this chapter

More chapters in Management for Professionals from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().